# Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old

> **NCT07187375** · PHASE2 · RECRUITING · sponsor: **Neurocrine Biosciences** · enrollment: 6 (estimated)

## Conditions studied

- Congenital Adrenal Hyperplasia

## Interventions

- **DRUG:** Crinecerfont

## Key facts

- **NCT ID:** NCT07187375
- **Lead sponsor:** Neurocrine Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-30
- **Primary completion:** 2029-09-06
- **Final completion:** 2029-10-04
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07187375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07187375, "Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT07187375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*